Center for Breakthrough Medicines signs agreement to manufacture jCyte's retinal degenerative disease cell therapy

Center for Breakthrough Medicines signs agreement to manufacture jCyte’s retinal degenerative disease cell therapy

jCell is a regenerative cell therapy for retinitis pigmentosa (RP) and other retinal degenerative diseases, which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Under the terms of the agreement, CBM will provide supplies for Phase 3 clinical trials and a commercial drug upon approval of the Biological License Application (BLA) of …

Center for Breakthrough Medicines signs agreement to manufacture jCyte’s retinal degenerative disease cell therapy Read More »